Analysed BIOMEA FUSION INC (BMEA:NASDAQ) News Sources
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
30-03-2026
marketbeat.com
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
31-03-2026
yahoo.com
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
27-04-2026
yahoo.com
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
28-04-2026
marketbeat.com
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026
05-05-2026
marketbeat.com
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
05-05-2026
yahoo.com
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
11-05-2026
yahoo.com
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
03-06-2026
yahoo.com
What is the current price of BIOMEA FUSION INC (BMEA:NASDAQ)?
The current price of BIOMEA FUSION INC (BMEA:NASDAQ) is $1.17.
BIOMEA FUSION INC (BMEA:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOMEA FUSION INC (BMEA:NASDAQ) since the previous trading day is $-0.02.
BIOMEA FUSION INC (BMEA:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOMEA FUSION INC (BMEA:NASDAQ) since the previous trading day is -1.6807%.
What is the most recent average sentiment score for BIOMEA FUSION INC (BMEA:NASDAQ)?
The most recent average sentiment score for BIOMEA FUSION INC (BMEA:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for BIOMEA FUSION INC (BMEA:NASDAQ)?
The most recent sentiment for BIOMEA FUSION INC (BMEA:NASDAQ) is .
SEC-8K** Filing Available For BIOMEA FUSION INC (BMEA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.